VM

Viemed Healthcare, Inc.

VMDHealthcareNASDAQ

Medical Devices · Last scanned Jul 16, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$270.3M
+20.5% YoY
Net Income
$14.9M
+32.6% YoY
EBITDA
$51.6M
+21.9% YoY
Free Cash Flow
$28.3M

Scan Results

Daily timeframe
3 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 11 RSI OverboughtRSI 84.9, above 70, stock may be overbought
Jul 10 RSI OverboughtRSI 85.3, above 70, stock may be overbought
About Viemed Healthcare, Inc.

Headquartered within the healthcare sector, Viemed Healthcare, Inc. focuses on Medical Devices services and products. Viemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States. At a $455.4M market cap, Viemed Healthcare, Inc. ranks as a small-cap company within healthcare. The company provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD.

Key stats
Market Cap$455.4M
P/E (TTM)32.11
Fwd P/E29.70
EPS$0.37
Beta1.10
52W Change+77.6%
ROE10.9%
Analysis

Viemed Healthcare, Inc. carries $12.4M in total debt against $9.8M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $28.3M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 10.9%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.3% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $138.8M (2022) to $270.3M (2025), reflecting a 95% increase over the period.

Investors considering Viemed Healthcare, Inc. should weigh the typical risks associated with VMD's sector, size, and financial profile against their own risk tolerance and investment objectives. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing VMD.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms